Prevention of Bone loss in HIV-infected patients taking Highly Active Antiretroviral Therapy with Zoledronate
A two year double blind, randomised, controlled trial to evaluate the efficacy of zoledronic acid in the prevention of bone loss in patients infected with human immunodeficiency virus taking highly active antiretroviral therapy (HAART)
Associate Professor A Grey
70 participants
Feb 5, 2003
Interventional
Conditions
Summary
This is a 2 year study designed to determine whether the use of an annual dose of zoledronate prevents bone loss associated with HIV infection
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
4mg intravenous zoledronate given annually for 2 years compared with placebo. All participants will also take 50,000u calciferol monthly and 400mg calcium daily.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12605000208606